Edition:
United Kingdom

People: Cara Therapeutics Inc (CARA.OQ)

CARA.OQ on NASDAQ Stock Exchange Global Market

22.93USD
23 Aug 2019
Change (% chg)

$-1.06 (-4.42%)
Prev Close
$23.99
Open
$23.80
Day's High
$24.25
Day's Low
$22.81
Volume
194,119
Avg. Vol
247,579
52-wk High
$27.50
52-wk Low
$12.20

Vogelbaum, Martin 

Mr. Martin Vogelbaum serves as an Lead Independent Director of the company. Mr. Vogelbaum currently serves as Managing Partner of Inning One Ventures, a life science venture capital fund. Previously, Mr. Vogelbaum served as Corporate Vice President, Business Development at Celgene Corporation from 2015 to 2017. Mr. Vogelbaum served as a partner of Rho Ventures from 2005 until 2015 and again from 2017 to 2018, where he focused on investments in biotechnology, biopharmaceuticals and medical devices. He has more than 25 years of experience investing in the life sciences sector, having been involved with companies at all stages of development, including co-founding more than a half dozen companies. Prior to his venture capital career, he was a research associate in the bone marrow transplantation unit at Memorial-Sloan Kettering Hospital, where he conducted research in graft-versus-host-disease. Mr. Vogelbaum previously served as a director of Inotek Pharmaceuticals Corporation (Nasdaq: ITEK) from 2010 to 2016 and NephroGenex, Inc. (Nasdaq: NRX) from 2013 to 2014. He currently serves on the Healthcare Advisory Board for the Partnership Fund for New York City as well as the Scientific Advisory Committee for Weill Cornell Medical College’s Daedalus Fund for Innovation. Mr. Vogelbaum received his A.B. in biology and history from Columbia University. Mr. Vogelbaum’s experience in the life sciences industry as a venture capitalist provides him with the qualifications and skills to serve on our Board of Directors.

Basic Compensation

Total Annual Compensation, USD 108,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 224,261
Fiscal Year Total, USD 332,261

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Derek Chalmers

2,789,050

Mani Mohindru

4,046,470

Frederique Menzaghi

1,238,230

Scott Terrillion

--

Joana Goncalves

3,736,190

Martin Vogelbaum

332,261
As Of  31 Dec 2018